The Retention Rate and Safety of Secukinumab as a First-Line Biologic Agent in Axial Spondyloarthritis Compared to a First Tumor Necrosis Factor (TNF) Inhibitor: A Real-World, Longitudinal StudyS. Zemrani, R. Bahiri, Bouchra Amine et al.|Cureus|2024Cited by 2
Tuberculosis Under Biotherapy in Patients with Spondyloarthritis: Data from the Moroccan Biotherapy Registry (RBSMR) during 3 Years of Follow UpS. Zemrani, R. Bahiri, Bouchra Amine et al.|Mediterranean Journal of Rheumatology|2025Cited by 1
Tuberculose active sous biothérapies chez les patients atteints de spondyloarthrites : résultats du registre marocain des biothérapies (RBSMR) à 3 ans de suiviS. Zemrani, B. Rachid, Bouchra Amine et al.|Revue du Rhumatisme|2023Cited by 0